The Oregon State Newsletter – June 2022 has been posted to the NABP/Oregon website and includes the following information.
- No. 678 Safe Pharmacy Practice Conditions
- No. 679 Expedited Partner Therapy Updates
- No. 680 Rulemaking
- Rule Feedback
- Permanent Rules Adopted in April 2022
- Permanent Rules Adopted in June 2022
- No. 681 Compliance: Legal Advice vs Legal Information
- No. 682 Licensing: Technician Renewals Due June 30, 2022
- No. 683 REALD and Pharmacies
Also in Oregon, the Board of Pharmacy adopted the following temporary rules effective July 1, 2022, through December 27, 2022.
- OAR 855-019-0210 related to Duties of Pharmacist Receiving a Prescription
- OAR 855-139-0699 related to a Retail Drug Outlet RDSP (Remote Dispensing Site Pharmacy)
Also in Oregon, the Board of Pharmacy adopted the following permanent rules at the June 2022 Board Meeting.
- Divisions 006/041/043/045/080/139 – related to Standards Adopted by Reference & Definitions - Effective June 16, 2022
- Divisions 019/025/041 – related to Certified Oregon Pharmacy Technician/Pharmacy Technician Final Verification - Effective June 16, 2022
- Divisions 019/041/139 – related to Interpreters – Effective September 1, 2022
- Divisions 019/143 – related to Pharmacy Prescription Lockers - Effective June 16, 2022
- Division 020 – related to Pharmacist Prescriptive Authority – Tobacco Cessation & PrEP - Effective June 16, 2022
- Division 031 – related to Public Health Emergency Sunset – Effective June 16, 2022
- Division 041 – related to Telework – Effective June 16, 2022
- Divisions 041/139 – related to Permanent Pharmacy Closure Requirements – Effective June 16, 2022
- Division 080 – related to Pseudoephedrine/Ephedrine & Interns – Effective June 16, 2022
- Division 110 – related to Drug Outlet Categories – Effective June 16, 2022
- Division 139 – related to RDSP [Remote Dispensing Site Pharmacies] – Effective June 16, 2022
Finally in Oregon, effective July 1, 2022, through December 27, 2022, the Oregon Health Authority adopted a temporary rule amending OAR 410-121-0030 and 410-121-0040 in accordance with the Drug Use Review (DUR) Pharmacy & Therapeutics (P&T) Committee’s recommendations made during the June 2, 2022 meeting.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.